Search Studies
Research studies are looking for volunteers just like you. Both healthy volunteers and participants with specific health conditions are needed to help answer important questions impacting the health of our friends and family. Join us to improve the health of others.
-
Blocking Orexin Receptors to Help Treat Alcohol Addiction and Stress-Driven Drinking
Official Title OASIS - Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related DrinkingPurpose
This study will look at whether suvorexant can help treat alcohol use disorder, how it works, and who it works best for. Suvorexant is a medicine that blocks certain brain signals linked to wakefulness.
Your total participation time in this study will be approximately 9 weeks.
Could this study be right for you?
Inclusion Criteria:
- Age 18-65
- Participant is able to give informed consent
- Engage in heavy alcohol use defined as drinking ≥14 standard drinks per week if male and ≥7 standard drinks per week if female.
General - Exclusion Criteria
- Clinically significant medical or neurological condition (e.g., liver disease, narcolepsy, complex sleep behaviors, severe hepatic impairment, COPD, severe obstructive sleep apnea)
- Current or past DSM-5 diagnosis of mania, schizophrenia, psychosis
- Past suicide attempt within 3 years or presence of moderate suicidal ideation
- Engage in night-shift work
Age Range
18 - 65 years -
Improving Physical Ability and Cellular Senescence Elimination in HIV
Official Title Improving Physical Ability and Cellular Senescence Elimination in HIV (IPACE-HIV)Purpose
The purpose of this study is to evaluate the safety and tolerability of dasatinib and quercetin (D+Q) and efficacy of this regimen in improving physical function outcomes in people with HIV (PWH) who are frail or prefrail.
Could this study be right for you?
- People living with HIV ≥50 years diagnosed with HIV 10 or more years ago
- Currently on combination antiretroviral therapy
- Currently virologically suppressed
- Must meet FFP criteria & have 4-meter gait speed in the range of .5-1.2 m/sec
Age Range
50 years and up -
An Infusion Study for Patients with Newly Diagnosed Type 1 Diabetes
Official Title A randomized, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)Purpose
This study is testing a medicine called teplizumab to see if it can help people aged 18 to 25 who were recently diagnosed with Type 1 Diabetes (T1D). The goal is to find out if teplizumab can protect the cells in the body that make insulin, which helps control blood sugar.
People with T1D usually lose these insulin-producing cells over time, and this study wants to see if teplizumab can slow down or stop that process. Everyone in the study will continue using insulin as usual, but some will also get teplizumab (or a placebo, which has no medicine) through IV infusions.
Researchers hope this treatment will:
-
Help the body keep making some of its own insulin
-
Reduce the amount of insulin people need to take
-
Improve blood sugar control
-
Lower the risk of very low blood sugar levels
The study will last about 84 weeks (a little over a year and a half), and participants will have regular checkups and tests to see how well the medicine works and how safe it is.
Could this study be right for you?
- Must be diagnosed with Type 1 Diabetes in the past 2 months
- Must have had a positive test for at least one Type 1 Diabetes antibody
- For female participants of childbearing potential - must use a contraception method (or abstinence)
Age Range
18 - 25 years -
-
A Study to Evaluate Investigation Drug, BHV-7000, in Patients with Refractory Focal Onset Epilepsy
Official Title A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects with Refractory Focal Onset EpilepsyPurpose
This research is being done to see the effectiveness and safety of a new drug called BHV-7000 as a possible treatment for focal seizures for patients who are taking anti-seizure medications (ASMs) and still experiencing seizures. Refractory focal epilepsy is when someone continues to have focal seizures despite treatment with ASMs or other treatments.
People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and the study includes up to 7 in-person visits.
Could this study be right for you?
- Experiencing at least 4 or more observable focal seizures per month
- Taking at least 1 and up to 3 anti-seizure medications
- Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 6 months
- Between the ages of 18 to 75
Age Range
18 - 75 years -
Phase 3 Study to Evaluate Investigational Drug, XEN1101, in Patients with Primary Generalized Tonic-Clonic Seizures: XPF-010-303
Official Title A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresPurpose
In this research study a study drug named XEN1101 is being tested for the treatment of seizures. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use. People who take part in this study will be randomly assigned to either study medication or a placebo, will participate for up to 5 months, and includes up to 7 in-person visits.
Could this study be right for you?
- Experiencing at least 3 PGTCS in an 8-week period
- Have tried at least 2 anti-seizure medications without success
- Do not have a history of cluster/repetitive seizures (which you were not able to individually count) in the past 12 months
- 18 years old and up
Age Range
18 years and up -
A Study Evaluating How Dietary Oils Effect Muscle Function and Strength
Official Title The Foods and Oils to Repair Correct and Enhance Strength (FORCES) Study: Determining the effect of dietary oils on muscle function, strength and massPurpose
The purpose of the FORCES Study is to determine how dietary oils effect muscle function, strength and mass in older adults who feel their muscle function and strength has declined with age.
During this 27-week study participants will
-
Consume ~2.5 tsp of oil each day through foods
-
Complete muscle function and strength testing
-
Have their blood drawn
-
Have their body weight and composition measured
-
Have an MRI scan of your legs, if able
-
Fill out questionnaires
-
Collect a small amount of muscle tissue from the leg (muscle biopsy
Could this study be right for you?
Feel your muscle function, strength or mass as decreased with age
Do NOT have food allergies
Are not taking any weight loss medications or following a weight loss program
Age Range
65 - 80 years -
-
Ketogenic Diet Intervention to Improve Response to Immunotherapy: KetoIO
Official Title Phase I Study of the Safety and Feasibility of a Ketogenic Dietary Intervention to Improve Response to ImmunotherapyPurpose
This study will look at if a ketogenic diet (KD) can help treatment work better in patients with metastatic melanoma or metastatic kidney cancer. People who take part in the study will be randomly assigned to either continue eating their usual diet or trying the KD diet for 24 weeks. Participants will have blood and stool samples collected during the study. They will also test their sugar by doing daily glucose fingers sticks. Participants may be paid up to $200 for taking part in the study.
Could this study be right for you?
- Patients with metastatic melanoma receiving first-line treatment with immunotherapy or Patients with metastatic renal cell cancer receiving first line treatment with immunotherapy.
- Willing to give three stool samples
- Willing to participate in a ketogenic diet (KD)
Age Range
18 years and up -
The Perceptions of Gen Zs Regarding the Dietary Guidelines for Americans (DGA)
Official Title The Knowledge and Perceptions of Gen Zs Regarding the Dietary Guidelines for AmericansPurpose
- Use ideas from Social Cognitive Theory to describe Gen Zs regarding the Dietary Guidelines for Americans (DGA) 2020 to 2025
- Explain what Gen Z knows and believes regarding the MyPlate recommendations for healthy eating related to:
- Filling half their plate with fruit and vegetables
- Filling one-quarter of their plate with lean protein, and varying the sources of protein
- Filling one-quarter of their plate with grains, making half of the grains whole grains
- To describe the associations between demographic variables (ethnicity, education, household income, and home environment) and Gen Zs perceptions and knowledge of the DGA
Could this study be right for you?
18 to 28 years old
Live in the US
English speaker
Have access to a device that supports Zoom
Age Range
18 - 28 years -
Smartphone-based HIV-specific Smoking Cessation Study
Official Title AMC-111 Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility StudyPurpose
This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.
In this study, you will have lung cancer screening performed via a CT scan. You will also be enrolled into a self-guided smartphone-based HIV-specific smoking cessation intervention called “Positively Smoke Free - Mobile” lasting 42 days. After starting the intervention, you will be evaluated at 3, 6, and 12 months.
Could this study be right for you?
Must have at least a 20 pack-year history of smoking (a way to measure how much a person has smoked over time, 1 pack-year is a pack per day for a year or 2 packs of cigarettes for half a year, etc.)
Must have not had a CT scan in the past 12 months
HIV positive, and must be receiving antiretroviral therapy and have a CD4 count of at least 200cells/uL within 6 months of enrolling in the study
Able to understand and provide informed consent
Possess a smart phone that can browse the web
Not receiving any other smoking cessation interventions currently or within the prior 30 days
Female volunteers cannot be pregnant, lactating, or breast-feeding
Age Range
45 - 80 years -
A Study to Evaluate Remibrutinib in Adults with Moderate to Severe Hidradenitis Suppurativa
Official Title A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis suppurativaPurpose
This study is being done to see how well remibrutinib works for people who have hidradenitis suppurativa
Could this study be right for you?
- Subject must have a diagnosis of moderate to severe hidradenitis suppurativa (HS) for at least 6 months with lesions in 2 distinct areas
- Subject must be in good general health with no history of tuberculosis, HIV, or hepatitis B or C
- Subject must have no recent history (within 6 months) of significant medical conditions such as a heart attack or stroke
- Subject must not be taking anticoagulant medication (ex. warfarin) or dual anti-platelet therapy (ex. acetylsalicylic acid + clopidogrel)
Age Range
18 years and up -
A Long-term, observational study on the safety of TZIELD for patients with Stage 2, Type 1 Diabetes
Official Title AN OBSERVATIONAL, LONG-TERM SAFETY STUDY OF TZIELD® (TEPLIZUMAB-MZWV) IN PATIENTS WITH STAGE 2 TYPE 1 DIABETESPurpose
The objective of the study is to test the safety and efficacy of TZIELD over the course of 10 years in patients with Stage 2, Type 1 Diabetes, as well as the prevention of Stage 3, Type 1 Diabetes.
Could this study be right for you?
Inclusion Criteria:
TZIELD-Exposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D who are planned to initiate TZIELD treatment according to the currently approved label or who have initiated TZIELD treatment within 6 months prior to enrollment:
− Day 1: 65 μg/m²
− Day 2: 125 μg/m²
− Day 3: 250 μg/m²
− Day 4: 500 μg/m²
− Days 5 through 14: 1,030 μg/m² per day
− Cumulative dose is approximately 11,240 μg/m²2. Appropriate written informed consent/assent as applicable for the age of the patient
TZIELD-Unexposed Cohort
1. Patients in the US diagnosed with Stage 2 T1D but who are not treated with TZIELD
2. Appropriate written informed consent/assent as applicable for the age of the patient
Exclusion Criteria:
1. Patients who initiated TZIELD treatment more than 6 months prior to enrollment
2. Patients who had participated in a previous clinical trial for TZIELD
3. Patients in an ongoing clinical trial of an investigational product or who had ended participation within 6 months prior to study enrollment; patients participating in other observational studies may be enrolled.Age Range
18 - 70 years -
Research Study on the Biomechanics of Total Knee Replacements
Official Title Biomechanical Metrics of Movement Relative to Total Knee ArthroplastyPurpose
This study aims to understand how a total knee replacement surgery (TKR) affects muscle function and movement in the lower body. It focuses on four key areas:
-
Examining how TKR changes the way muscles work in the lower body.
-
Exploring how these muscle changes relate to the forces people experience when walking and doing daily activities after surgery.
-
Connecting muscle function to how well patients feel and move after TKR.
-
Identifying different types of TKR patients based on their physical traits, movement patterns, and medical history to see how they compare.
Could this study be right for you?
- Must be scheduled to receive a total knee replacement within the next 2 months
- Have a body mass index (BMI) < 40
- Do not require the use of a cane or other assistive device when walking, climbing stairs, and getting up from a chair
Exclusion criteria varies; please contact Study Coordinator for more information
Age Range
18 years and up -